Here's why the Opthea (ASX:OPT) share price is soaring 8%

This biopharmaceutical company is developing therapies to treat progressive retinal diseases.

| More on:
A woman sits inside a cubicle undergoing an eyetest

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Opthea Ltd (ASX: OPT) share price is soaring today, up more than 8% trading at $1.37 at the time of writing.

The clinical stage biopharmaceutical company is focused on developing therapies to treat progressive retinal diseases.

Below, we look at the company's latest update from its United States' endeavours.

What update did Opthea announce?

Opthea's share price is rocketing after the company reported that it had received Fast Track designation from the US Food and Drug Administration (FDA) for its product to treat patients with neovascular (wet) age-related macular degeneration (AMD).

Opthea said the Fast Track designation for its VEGF-C/-D 'trap' inhibitor, OPT-302, used in combination with anti-VEGF-A therapy, recognises the potential role that OPT-302 has for addressing significant unmet needs to manage neovascular AMD.

The FDA's Fast Track designation opens the door to Opthea for improved communications with the administration. It said a rolling review process enabled by the designation will help speed up its Phase 3 development program and approval review processes.

It noted that OPT-302 may now also be eligible for accelerated approval and priority review as long as it meets the needed criteria.

Commenting on the Fast Track approval, Opthea's CEO Megan Baldwin said:

The recognition from the FDA to grant OPT-302 Fast Track designation reflects the seriousness of wet AMD as a debilitating eye disease and the importance of advancing new therapies such as OPT-302 to address the significant unmet medical need for wet AMD patients, many of whom experience an incomplete response to VEGF-A inhibitors despite regular, ongoing therapy.

By targeting a novel mechanism of action, OPT-302 has the potential to be a truly differentiated treatment option that when used in combination offers patients improved vision outcomes over standard of care anti-VEGF-A monotherapy.

Opthea said it was currently recruiting patients for 2 simultaneous global Phase 3 trials, with some 990 patients expected in each.

Opthea share price snapshot

Despite today's rise, the Opthea share price remains down 45% over the past 12 months, during a period that saw the All Ordinaries Index (ASX: XAO) gain 24%.

Year-to-date, the Opthea share price has remained under pressure, down 30%.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »